Evidence map›Paper›PMID 36831311›Full record

ArticleCells2023

Implications of Senescent Cell Burden and NRF2 Pathway in Uremic Calcification: A Translational Study.

Jonas Laget, Sam Hobson, Karen Muyor, Flore Duranton, Irene Cortijo, Piotr Bartochowski, Bernard Jover, Anne-Dominique Lajoix, Magnus Söderberg, Thomas Ebert and 4 more

Open access · goldAbstract read
In one paragraph

Article in Cells, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. High-flux hemodialysis with polymethylmethacrylate membranes reduces soluble CD40L, a mediator of cardiovascular disease in uremia.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025
    Trial
  2. Kidney Disease as a Driver of Immunosenescence: Mechanisms and Potential Interventions.Journal of the American Society of Nephrology : JASN · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Jonas LagetRD-Néphrologie, 34090 Montpellier, France.ORCID 0000-0002-9095-7409
Sam HobsonDivision of Renal Medicine, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, 141 52 Stockholm, Sweden.ORCID 0000-0002-5880-885X
Karen MuyorRD-Néphrologie, 34090 Montpellier, France.
Flore DurantonRD-Néphrologie, 34090 Montpellier, France.ORCID 0000-0003-3202-0551
Irene CortijoRD-Néphrologie, 34090 Montpellier, France.
Piotr BartochowskiRD-Néphrologie, 34090 Montpellier, France.
Bernard JoverRD-Néphrologie, 34090 Montpellier, France.ORCID 0000-0001-5826-5755
Anne-Dominique LajoixBiocommunication in Cardio-Metabolism (BC2M), University of Montpellier, 34090 Montpellier, France.ORCID 0000-0002-5912-5233
Magnus SöderbergPathology, Clinical Pharmacology and Safety Sciences, R&D AstraZeneca, 431 50 Gothenburg, Sweden.ORCID 0000-0003-0946-5202
Thomas EbertDivision of Renal Medicine, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, 141 52 Stockholm, Sweden.ORCID 0000-0003-1683-9276
Peter StenvinkelDivision of Renal Medicine, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, 141 52 Stockholm, Sweden.ORCID 0000-0002-8785-4820
Àngel ArgilésRD-Néphrologie, 34090 Montpellier, France.ORCID 0000-0001-7029-4532
Karolina KublickieneDivision of Renal Medicine, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, 141 52 Stockholm, Sweden.ORCID 0000-0002-4841-6836
Nathalie GayrardRD-Néphrologie, 34090 Montpellier, France.ORCID 0000-0001-8283-8429
Karolinska Institutet · SEUniversité de Montpellier · FRAstraZeneca (Sweden) · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Increased senescent cell burden and dysregulation of the nuclear factor erythroid 2-related factor 2 (NRF2) pathway have been associated with numerous age-related pathologies; however, their role in promoting vascular calcification (VC) in chronic kidney disease (CKD) has yet to be determined. We investigated whether senescence and NRF2 pathways may serve as drivers of uremia-induced VC using three complementary approaches: a novel model of induced VC in 5/6-nephrectomized rats supplemented with high phosphate and vitamin D; epigastric arteries from CKD patients with established medial calcification; and vascular smooth muscle cells (VSMCs) incubated with uremic serum. Expression of p16

Indexed as

Renal Insufficiency, ChronicVascular CalcificationAnimalsCellular SenescenceCyclin-Dependent Kinase Inhibitor p16Muscle, Smooth, VascularNF-E2-Related Factor 2RatsCyclin-Dependent Kinase Inhibitor p16NF-E2-Related Factor 2kidney failureNRF2senescencesubtotal nephrectomyvascular calcification

Identifiers

PMID36831311
PMCPMC9954542
OpenAlexW4321233952

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.